Napabucasin can inhibit DLBCL in vitro

  • Li X & al.
  • Cancer Lett
  • 13 Aug 2020

  • curated by Pavankumar Kamat
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • An in vitro study found napabucasin to be effective in inhibiting diffuse large beta cell lymphoma (DLBCL) in cell lines.
  • In addition, the effects of napabucasin were synergistic with the use of doxorubicin, a standard therapy for DLBCL.

Why this matters

  • Although the signal transducer and activator of transcription 3 (STAT3) pathway plays a key role in the development of many cancers, there have not been any drugs approved for clinical use yet.
  • Napabucasin is a novel, small-molecule inhibitor of STAT3.

Study design

  • Researchers tested the effects of napabucasin on various DLBCL cell lines. 
  • Funding: Chinese government.

Key results

  • 34% of patients with DLBCL expressed STAT3 in tumor tissues.
  • Napabucasin showed potent cytotoxicity in a dose-dependent manner. 
  • Napabucasin also induced intrinsic and extrinsic cell apoptosis; downregulated the expression of STAT3 target genes, including the antiapoptotic protein Mcl-1; and regulated the mitogen-activated protein kinase pathway.
  • In cells treated with napabucasin and doxorubicin alone and in combination, napabucasin alone significantly suppressed tumor growth compared with the control (P<.01 achieving tumor growth inhibition of>
  • The combination treatment was significantly more effective than doxorubicin monotherapy (TGI, 98.2% vs 63.2%; P<.05>

Limitations

  • In vitro findings may not reflect clinical efficacy.